Varenicline: 5 agencies, 2007–2025
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 18 years separate the first record, 23 Mar 2007 at TLV (Sweden), from the most recent, 12 Mar 2025 at HAS (France).
PHARMAC (New Zealand) changed its position: restricted on 11 Feb 2016, recommended by 24 Sep 2020.
No assessment is on file from SMC (Scotland), AWMSG (Wales), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
2 of these 10 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
TLV (Sweden) was first to assess varenicline, on 23 Mar 2007; HAS (France) did not open a file until 12 Mar 2025 — an unusually long tail of 18 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 5 of 10 dated records fall in 2016 alone.
Restriction is doing real work here: 3 of 10 decisive outcomes narrowed varenicline to a subgroup rather than accepting or refusing it outright, at PHARMAC (New Zealand) and TLV (Sweden).
2 of the 5 agencies here assessed varenicline more than once, PHARMAC (New Zealand) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 5 of the 18 agencies here have assessed varenicline.
The full ledger for varenicline reads 6 recommended, 3 restricted and 1 not recommended.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 12 Mar 2025 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| PBAC (Australia) | 2017 | Nicotine dependence | The PBAC recommended the amendment to the continuing treatment listing of varenicline to i… | source |
| PHARMAC (New Zealand) | 11 Feb 2016 | Smoking cessation - Reducing re-treatment period from 12 months to 6 months | PTAC advice: Low · decision reached | source |
| NICE (England) | 25 Jul 2007 | NICE TA123 | recommended | source |
| TLV (Sweden) | 23 Mar 2007 | Begränsad subvention för rökavvänjningsmedlet Champix | restricted subsidy | source |
5 further decisions for varenicline, across 2 agencies, are not shown here. They link to 4 further source documents.
Related molecules
- nicotine — same ATC class N07B — Other nervous system
- buprenorphine — same ATC class N07B — Other nervous system
- buprenorphine / naloxone — same ATC class N07B — Other nervous system
- nalmefene — same ATC class N07B — Other nervous system
- naltrexone — same ATC class N07B — Other nervous system
- vosoritide — also decided by HAS in 2025Q1
Coverage: 10 decisions for varenicline from 5 agencies, 2007 to 2025. Data to 7 Sep 2026. ATC class N07B — Other nervous system. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.